Although combined treatment with moclobemide and selegiline was well tolerated, the supra-additive potentiation of the tyramine pressor effects means that dietary restriction of tyramine intake will be necessary during such combination therapy.
Moclobemide was compared with clomipramine for safety and efficacy in 2 groups of 15 patients each with endogenous depression. The drugs were given under double‐blind conditions in increasing doses; 1 patient in the moclobemide group dropped out because of lack of efficacy. Mean final improvement on the Hamilton Rating Scale for Depression was 51% in the moclobemide group and 54% in the clomipramine group. Efficacy and tolerance were rated good or very good by 47% (moclobemide) and 53%o (clomipramine) (NS). The results indicate that moclobemide is as effective as clomipramine in treating endogenous depression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.